Cargando…

Effects of JWH015 in cytokine secretion in primary human keratinocytes and fibroblasts and its suitability for topical/transdermal delivery

BACKGROUND: JWH015 is a cannabinoid (CB) receptor type 2 agonist that produces immunomodulatory effects. Since skin cells play a key role in inflammatory conditions and tissue repair, we investigated the ability of JWH015 to promote an anti-inflammatory and pro-wound healing phenotype in human prima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bort, Alicia, Alvarado-Vazquez, Perla A, Moracho-Vilrriales, Carolina, Virga, Kristopher G, Gumina, Giuseppe, Romero-Sandoval, Alfonso, Asbill, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302180/ https://www.ncbi.nlm.nih.gov/pubmed/28326930 http://dx.doi.org/10.1177/1744806916688220

Ejemplares similares

Cytokine production capabilities of human primary monocyte-derived macrophages from patients with diabetes mellitus type 2 with and without diabetic peripheral neuropathy
por: Alvarado-Vázquez, Perla Abigail, et al.
Publicado: (2018)

Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice
por: Verty, A. N. A., et al.
Publicado: (2015)

Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
por: Hanlon, Katherine E, et al.
Publicado: (2016)

Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176
por: Tampus, Reinholdgher, et al.
Publicado: (2015)

Neurotoxicity of Synthetic Cannabinoids JWH-081 and JWH-210
por: Cha, Hye Jin, et al.
Publicado: (2015)

Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches
por: Cha, Hye Jin, et al.
Publicado: (2014)

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2)
por: Olea-Herrero, N, et al.
Publicado: (2009)

Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor
por: Fechtner, Sabrina, et al.
Publicado: (2019)

The Antinociceptive Effects of JWH-015 in Chronic Inflammatory Pain Are Produced by Nitric Oxide-cGMP-PKG-KATP Pathway Activation Mediated by Opioids
por: Negrete, Roger, et al.
Publicado: (2011)

In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamic and Pharmacokinetic Studies in Mice
por: Tirri, Micaela, et al.
Publicado: (2022)

Identification, prevalence, and treatment of painful diabetic neuropathy in patients from a rural area in South Carolina
por: Pruitt, Jimmy, et al.
Publicado: (2017)

Data on individual metabolites of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans
por: Watanabe, Shimpei, et al.
Publicado: (2016)

Cannabinoid receptor 2-selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord
por: Mao, Yanting, et al.
Publicado: (2019)

Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ(9)-THC in Rats
por: Uttl, Libor, et al.
Publicado: (2018)

Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study
por: Martínez, Lucia, et al.
Publicado: (2021)

Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS
por: La Maida, Nunzia, et al.
Publicado: (2020)

Effect of Topical Brimonidine 0.15% on Conjunctival Injection after Strabismus Surgery in Children
por: Kim, Dong Hyun, et al.
Publicado: (2021)

Transdermal and Topical Drug Administration in the Treatment of Pain
por: Leppert, Wojciech, et al.
Publicado: (2018)

The Skin and Natural Cannabinoids–Topical and Transdermal Applications
por: Filipiuc, Silviu-Iulian, et al.
Publicado: (2023)

Self-Administration of JWH-018 A Synthetic Cannabinoid in Experimentally Naïve Rats
por: Hiranita, Takato
Publicado: (2015)

Film forming systems for topical and transdermal drug delivery
por: Kathe, Kashmira, et al.
Publicado: (2017)

Elevation of endocannabinoids in the brain by synthetic cannabinoid JWH-018: mechanism and effect on learning and memory
por: Li, Ren-shi, et al.
Publicado: (2019)

A Snapshot of Transdermal and Topical Drug Delivery Research in Canada
por: Roohnikan, Mahdi, et al.
Publicado: (2019)

Efficacy, Safety and Targets in Topical and Transdermal Active and Excipient Delivery
por: Mohammed, Yousuf H., et al.
Publicado: (2017)

Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as ∆9-tetrahydrocannabinol to pigs
por: Schaefer, Nadine, et al.
Publicado: (2020)

Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies
por: Benson, Heather A.E., et al.
Publicado: (2019)

Metabolomic Alteration of Oral Keratinocytes and Fibroblasts in Hypoxia
por: Kato, Hiroko, et al.
Publicado: (2021)

Activation of cannabinoid receptor type 2 by JWH133 alleviates bleomycin-induced pulmonary fibrosis in mice
por: Fu, Qiang, et al.
Publicado: (2017)

Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and ∆ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs
por: Schaefer, Nadine, et al.
Publicado: (2017)

Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders
por: Theunissen, Eef L., et al.
Publicado: (2019)

Modified Alginate-Based Hydrogel as a Carrier of the CB2 Agonist JWH133 for Bone Engineering
por: Zhou, Wei, et al.
Publicado: (2021)

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis
por: Theunissen, Eef L., et al.
Publicado: (2021)

Synthetic cannabinoid JWH-073 alters both acute behavior and in vivo/vitro electrophysiological responses in mice
por: Barbieri, Mario, et al.
Publicado: (2022)

ODP015 "Malignant" Hypertension in an Older Male
por: Naha, Sowjanya, et al.
Publicado: (2022)

Development of a Silicone-Based Polymer Matrix as a Suitable Transdermal Therapeutic System for Diallyl Disulfide
por: László, Szabolcs, et al.
Publicado: (2022)

Development of Betamethasone Dipropionate-loaded Nanostructured Lipid Carriers for Topical and Transdermal Delivery
por: Hanna, Pierre A., et al.
Publicado: (2019)

Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications
por: Akombaetwa, Nakamwi, et al.
Publicado: (2023)

Treatment with CB(2) Agonist JWH-133 Reduces Histological Features Associated with Erectile Dysfunction in Hypercholesterolemic Mice
por: Fraga-Silva, Rodrigo Araujo, et al.
Publicado: (2013)

Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist
por: Hashiesh, Hebaallah Mamdouh, et al.
Publicado: (2021)

CB2 Receptor Agonist JWH133 Activates AMPK to Inhibit Growth of C6 Glioma Cells
por: Wang, Feng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t36qb46npnpqdjek86ch04s6hu